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Classical swine fever virus (CSFV) E2 glycoprotein contains a discrete epitope (TAVSPTTLR, residues 829–837 of CSFV polyprotein)
recognized by monoclonal antibody (mAb) WH303, used to differentiate CSFV from related ruminant pestiviruses, Bovine Viral Diarrhea Virus
(BVDV) and Border Disease Virus (BDV), that infect swine without causing disease. Progressive mutations were introduced into mAb WH303
epitope in CSFV virulent strain Brescia (BICv) to obtain the homologous amino acid sequence of BVDV strain NADL E2 (TSFNMDTLA). In
vitro growth of mutants T1v (TSFSPTTLR), T2v (TSFNPTTLR), T3v (TSFNMTTLR) was similar to parental BICv, while mutants T4v
(TSFNMDTLR) and T5v (TSFNMDTLA) exhibited a 10-fold decrease in virus yield and reduced plaque size. In vivo, T1v, T2v or T3v induced
lethal disease, T4v induced mild and transient disease and T5v induced mild clinical signs. Protection against BICv challenge was observed at 3
and 21 days post-T5v infection. These results indicate that E2 residues TAVSPTTLR play a significant role in CSFV virulence.
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Classical swine fever (CSF) is a highly contagious disease of
swine that can be either acute or chronic in nature (Van
Oirschot, 1986). The etiological agent, CSF virus (CSFV), is a
small, enveloped virus with a positive, single-stranded RNA
genome and, along with Bovine Viral Diarrhea Virus (BVDV)
and Border Disease Virus (BDV), is classified as a member of
the genus Pestivirus within the family Flaviridae (Francki et
al., 1991). The 12.5 kb CSFV genome contains a single open⁎ Corresponding author. Fax: +1 631 323 3006.
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and ultimately yields 11 to 12 final cleavage products (NH2-
Npro-C-Erns-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-
COOH) through co- and post-translational processing of the
polyprotein by cellular and viral proteases (Rice, 1996).
Structural components of the CSFV virion include the capsid
(C) protein and glycoproteins Erns, E1 and E2. E1 and E2 are
anchored to the envelope by their carboxyl termini and Erns
loosely associated with the viral envelope (Thiel et al., 1991;
Weiland et al., 1990, 1999).
Virulence and host range phenotypes vary among CSFV
isolates and between pestiviruses. Infection with highly virulent
CSFV strains leads to death in infected animals, whereas
isolates of moderate to low virulence induce a prolonged
chronic disease (Van Oirschot, 1986). In addition, BVDV and
BDV, while etiologic agents of diseases in bovine and ovine
species, respectively, can also infect swine without inducing
clinical disease (Van Oirschot, 1986). Despite availability of
genomic sequences from CSFV of differing virulence
Fig. 1. Comparison of CSFV strain Brescia, BVDV strain NADL and CSFV
T1–5 mutant viruses in the mAb WH303 epitope region of E2 glycoprotein.
Amino acid residue positions in the CSFV polyprotein are indicated. Italics
indicate residues in BVDV strain NADL and CSFV T1v to T5v that are different
from those in Brescia.
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virulence in the natural host remains poorly understood (Van
Oirschot, 1986). The use of reverse genetics has enabled the
identification of viral determinants of virulence, facilitating
development of candidate live attenuated CSF vaccines (Mayer
et al., 2004, 1999; Moormann et al., 1996; Moser et al., 2001;
Risatti et al., 2005a, 2005b; Ruggli et al., 1996; Tratschin et al.,
1998; van Gennip et al., 2000). Notably, all three viral
glycoproteins have been associated with CSFV virulence
(Meyers et al., 1999; Risatti et al., 2005a, 2005b; van Gennip
et al., 2004). Erns mutants of strain Alfort/187 exhibited
different degrees of attenuation when inoculated in swine
(Meyers et al., 1999), and a 19 nucleotide insertion in the
carboxyl-end of the E1 gene caused complete attenuation of the
highly virulent strain Brescia (Risatti et al., 2005b). Recently,
the E2 gene from vaccine strain CS was shown to attenuate
chimeric CSFV containing a Brescia strain genetic background
(Risatti et al., 2005a). Further analysis of that chimeric virus
mapped the residues responsible for the attenuation at the
carboxyl-terminal half of E2 (Risatti et al., unpublished data).
E2 glycoprotein is considered essential for CSFV replication,
as virus mutants containing partial or complete deletions of the
E2 gene have proven non-viable (van Gennip et al., 2002). E2
has been implicated, along with Erns (Hulst and Moormann,
1997) and E1 (Wang et al., 2004), in viral adsorption to host
cells; indeed, chimeric pestiviruses exhibit infectivity and cell
tropism phenotypes consistent with those of the E2 gene donor
(Liang et al., 2003; van Gennip et al., 2000). E2 is the most
immunogenic of the CSFV glycoproteins (Konig et al., 1995;
Weiland et al., 1990), inducing neutralizing antibodies and
protection against lethal challenge (Hulst et al., 1993). CSFV E2
also contains between amino acid residues 829 and 837 an
epitope recognized by monoclonal antibody (mAb) WH303
(Lin et al., 2000), a reagent which fails to react with BVDVor
BDV E2 and is routinely used for CSF diagnostics. The amino
acid sequence comprising this epitope (TAVSPTTLR) is
invariant among known CSFV strains and differs substantially
from homologous sequences encoded by other pestiviruses,
suggesting that the WH303 epitope may play a significant role
during CSFV infection. Here we report the effects of mutations
within the WH303 epitope of CSFV E2 made progressively
toward the homologous amino acid sequence of BVDV strain
NADL, demonstrating an additive effect for viral virulence in
swine and complete attenuation after six amino-acid changes.
Interestingly, animals infected with virus mutants were
protected when challenged with virulent Brescia virus at 3
and 21 days post-vaccination.
Results
Construction of CSFV T1–T5 mutant viruses
Infectious RNA was in vitro transcribed from full-length
infectious clones (ICs) of CSFV strain Brescia or mutants T1 to
T5 and used to transfect SK6 cells (Fig. 1). Virus was rescued
from transfected cells by day 4 post-transfection. Nucleotide
sequences of the rescued virus genomes were identical toparental DNA plasmids, confirming that only mutations at the
locus encoding the WH303 epitope were reflected in T1v–T5v.
Replication of T1v–T5v in vitro
In vitro growth characteristics of T1v–T5v relative to
parental BICv were evaluated in a multistep growth curve
(Fig. 2A). SK6 cell cultures were infected at a multiplicity of
infection (MOI) of 0.01 TCID50 per cell. Virus was adsorbed for
1 h (time zero), and samples were collected at times post-
infection through 72 h. While mutants T1v, T2v, and T3v
exhibited growth characteristics practically indistinguishable
from BICv, T4v and T5v exhibited a 10-fold decrease in the
final virus yield. T4v and T5v also exhibited a noticeable
reduction in plaque size relative to BICv, T1v, T2v and T3v
(Fig. 2B). Finally, while immunocytochemical reactivity with
the mAb WH303 was equivalent for T1v, T2v and BICv,
reactivity was partially lost in T3v and completely abolished in
T4v and T5v-infected cells (Fig. 2B). These results indicate that
mutations of the WH303 epitope affecting the ability of CSFV
to replicate in vitro have a similar effect on WH303 reactivity.
Mutants T4v and T5v lack determinants necessary for CSFV
virulence in swine
To examine the effect progressive WH303 epitope mutation
on CSFV virulence in swine, virulence phenotypes of T1v–T5v
mutant and BICv wild type viruses were compared in 6 groups
of pigs intranasally inoculated with 105 TCID50 of virus and
monitored for clinical disease. Results from this experiment are
shown in Table 1 and Figs. 3–5. Identity and stability of
WH303 epitope mutations were confirmed by nucleotide
sequence analysis of virus recovered from tonsils of T1v–
T5v-infected animals at 6 DPI (data not shown). While BICv, as
expected, was highly pathogenic, effectively inducing fever,
clinical signs and death in swine, T1v–T5v mutants appeared to
have virulence phenotypes that were increasingly attenuated
(Table 1, Fig. 3). T1v and T2v were also highly pathogenic,
inducing fever and death in swine in a manner similar to that of
Fig. 2. (A) In vitro growth characteristics of T1v–T5v mutants and BICv. SK6 monolayers were infected (MOI=0.01) with T1v, T2v, T3v, T4v, T5v or BICv and virus
yield titrated at times post-infection. Data represent means and standard deviations from two independent experiments. (B) Plaque formation and mAb reactivity of
mutants T1v–T5v and BICV. SK6 monolayers were infected with 50 to 100 TCID50, overlaid with 0.5% agarose and incubated at 37 °C for 3 days. Plates were fixed
with 50% (vol/vol) ethanol–acetone and differentially stained by immunohistochemistry with mAb WH303 and mAb WH308.
96 G.R. Risatti et al. / Virology 355 (2006) 94–101BICv (Table 1); however, T2v demonstrated a slight delay in
clinical scores relative to BICv (Fig. 3). T3v induced lethal
disease but with delayed kinetics relative to BICv, as death
occurred 4–8 days later (Table 1). Remarkably, T4v and T5v
failed to induce lethal disease, with T4v inducing only a mild
and transient clinical disease and T5v inducing mild clinical
signs (Table 1, Fig. 3). Similarly, BICv, T1v, T2v and T3v
infection by 6 DPI resulted in a drastic reduction in white blood
cell (WBC) and platelet counts which remained low until death,Table 1



















T1v 0/2 8.5 (2.1) 3.0 (1.4) 4.5 (2.1) 107.2 (0.0)
T2v 0/2 14.5 (2.1) 4.5 (0.7) 9.5 (0.7) 106.6 (1.7)
T3v 0/2 19.0 (0.0) 5.0 (0.0) 6.0 (1.4) 105.7 (1.6)
T4v 4/4a – 5.0 (0.0) 2.5 (2.1)b 106.2 (0.6)
T5v 6/6c – – – 104.8 (0.6)
BICv 0/6c 12.5 (2.1) 4.5 (0.7) 4.5 (0.7) 105.8 (0.3)
SD: standard deviation.
a Two independent experiments with 2 pigs in each experiment.
b Two out of 4 animals presented fever.
c Includes animals used in protection studies.while T4v and T5v-infected induced a transient and much less
dramatic effect (Fig. 4).
Attenuation of T1v–T5v was also reflected in viremia and
virus shedding. While T1v and T2v induced viremic titers
comparable to those induced by BICv, T3v titers were reduced
by 101 to 102 log10, and T4v and T5v induced titers 10
3 to 104
log10 lower than BICv titers at similar times post-infection (Fig.Fig. 3. Clinical scores recorded from pigs infected with recombinant viruses
T1v–T5v and BICv. Clinical Scores were calculated as previously described
with modifications (see Materials and methods) and were based on observations
of two (T1v, T2v, T3v and T4v) or six (T5v and BICv) animals.
Fig. 4. (A) Peripheral white blood cell and (B) platelet counts in pigs infected
with recombinant viruses T1v–T5v and BICv. Counts are expressed as numbers/
μl and each point represents the mean and standard errors for two (T1v, T2v, T3v
and T4v) or six (T5v and BICv) animals.
Fig. 5. Virus titers in (A) blood, (B) nasal swabs and (C) tonsil scrapings from
pigs infected with T1v–T5v mutants or BICv. Each point represents the mean
log10 TCID50/ml and standard deviation for two (T1v, T2v, T3v and T4v) or six
(T5v and BICv) animals.
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swabs and tonsil-scrapings (Figs. 5B and C, respectively), with
T3v, T4v and T5v titers falling below detectible levels at later
DPI.
For a more detailed study of T5v pathogenesis, T5v and
BICv-infected animals were euthanized at 2, 4, 6, 8 and 14 DPI
(one animal/time point/group) and virus titers determined for
tonsil, submandibular lymph node, spleen, blood and kidney
and for nasal swab and tonsil scraping samples (Table 2). T5v
exhibited significantly lower levels of virus replication in tonsils
(approximately 102 to 104 log10) relative to BICv. Similar
differences between T5v and BICv were observed in virus titers
from mandibular lymph node, spleen and kidney (Table 2).
These results indicate that an increasing number of mutations
within the WH303 epitope of CSFV E2 had an additive effect in
attenuating the virus for swine, with mutations present in T4v
and T5v resulting in significant decrease in viral virulence.
Furthermore, T5v infection is characterized by a decreased viral
replication in tonsils and target tissues, and dramatically
reduced virus shedding.
T5v infection protects swine against challenge with pathogenic
BICv
The ability of T5v to induce protection against BICv
challenge was evaluated. Swine vaccinated with T5v waschallenged at 3 or 21 DPI with 105 TCID50 of pathogenic
BICv. Mock vaccinated control pigs receiving no T5v and
challenged with BICv developed anorexia, depression and
fever by 4 days post-challenge (DPC), developed a marked
reduction of circulating leukocytes and platelets by day 7 DPC
and had died or were moribund and euthanized by 12 DPC
(Table 3).
Notably, T5v induced by 3 DPI complete protection against
BICv-induced clinical disease. All pigs survived infection and
remained clinically normal, with only two animals presenting
with a transient fever at 4 DPC (Table 3) and without significant
changes in their hematological values (Fig. 6). Similarly, pigs
challenged at 21 days post-T5v infection remained clinically
normal (Table 3).
Viremia and virus shedding of BICv challenge virus as
specifically detected with mAbWH303 was also examined at 4,
6, 8, 14 and 21 DPC (data not shown). As expected in mock-
vaccinated control animals, BICv viremia was observed by
Table 2
Virus titersa in clinical samples and tissues obtained from pigs following
infection with T5v or BICv
Virus T5v BICv
DPIb 2 4 6 8 14 2 4 6 8 14
Nasal swabs Negc 1.97 Neg Neg Neg Neg Neg 1.97 4.63 3.97
Tonsil
scrapings
Neg Neg 2.63 Neg Neg Neg Neg 1.97 4.97 2.97
Blood Neg NDd 2.97 3.97 Neg Neg 3.13 6.47 6.3 6.80
Tonsil 2.13 2.97 3.30 1.97 2.80 1.97 4.63 5.13 5.47 6.13
Mandibular
lymph node
2.80 3.30 3.63 2.47 3.30 1.8 2.80 4.80 5.80 5.97
Spleen Neg 2.97 2.63 3.47 2.80 Neg 2.13 2.80 5.63 6.30
Kidney Neg 2.47 2.977 3.13 2.13 Neg Neg 2.80 4.80 5.97
a Titers expressed as log 10 TCID50/ml.
b DPI, days post-infection.
c Neg: ≤1.80 log 10 TICD50/ml.
d ND: not determined.
Fig. 6. (A) Peripheral white blood cell and (B) platelet counts in pigs mock
vaccinated or vaccinated with T5v and challenged at 3 or 21 DPI with BICv.
Values for control, mock vaccinated and challenged animals, are represented
with empty squares. Counts are expressed as numbers/μl and represent the mean
of four individuals with error bars indicating standard error.
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8 DPC) until death, and BICv was titrated from nasal swabs and
tonsil scrapings by 4 DPC, reaching titers of 104–105 TCID50/
ml) by 8 DPC. In contrast, BICv was absent in all clinical
samples (blood, nasal swabs or tonsil scrapings) from T5v-
vaccinated swine following challenge. These results indicate
that T5v is able to rapidly induce complete protection against
lethal CSFV challenge, that T5v-immune swine demonstrate no
detectible viremia or shedding from challenge virus and that
T5v can be differentiated from wild-type virus via absence of
the WH303 epitope.
Discussion
Here, we have shown that mutations introduced into the
CSFV E2 glycoprotein at the CSFV-specific, mAb WH303 epi-
tope resulted in attenuation of highly pathogenic Brescia strain.
Amino acids of the CSFVWH303 epitope (TAVSPTTLR) were
progressively changed to resemble homologous residues
(TSFNMDTLA) of the BVDV strain NADL E2 glycoprotein.
Interestingly, mutant viruses encoding TSFNMDTLR (T4v) or
TSFNMDTLA (T5v) sequences lack reactivity to mAb
WH303, show small plaque morphology and are significantly
attenuated in vivo. Unlike the acute fatal disease induced by
BICv, T4v and T5v infections were subclinical in swine andTable 3






















3 4/4 – 4 (0.8)b 1 (0.0) 103.1 (0.6)
21 4/4 – – – 102.9 (0.3)
Controlc 0/4 12 (0.0) 4 (0.0) 5 (0.7) 105.9 (0.7)
SD: standard deviation.
a Days post-infection with T5v.
b Two out of 4 animals presented fever.
c Control: animals were mock vaccinated.characterized by decreased viral replication in target organs and
reduced virus shedding.
In general, the genetic bases and the molecular mechanisms
underlying CSFV virulence remain obscure, with few studies
associating specific viral proteins or genomic region with
virulence. Single or double codon mutation of Erns that
abrogated its RNase activity resulted in attenuation of CSFV
strain Alfort in swine and, similarly, mutation of the Erns RNase
domain of BVDV attenuated the virus in cattle (Meyers et al.,
1999, 2002). Complete deletion of Npro from virulent CSFV
strains Alfort/187 and Eystrup attenuated these viruses in swine
(Mayer et al., 2004), as did an in frame insertion of 19 amino
acids into the E1 gene of CSFV strain Brescia (Risatti et al.,
2005b). Replacement of the E2 gene in CSFV strain Brescia
with that of vaccine strain CS resulted in a chimeric virus that
has a significant in vivo attenuation, including significantly
decreased virus replication in tonsils, a transient viremia,
limited generalization of infection and decreased virus shedding
(Risatti et al., 2005a).
Findings presented here are the first to identify a discrete
amino acid sequence within E2 as a specific determinant of
CSFV virulence. A L710H substitution in E2 was previously
shown to affect CSFV virulence in swine; however, the
attenuated phenotype also required concomitant mutations in
Erns (van Gennip et al., 2004). Comparative sequence analysis
previously indicated that Brescia and CS strain E2 proteins
differed by 22 amino acids (Risatti et al., 2005a). Notably, the
mAb WH303 epitope identified here as a CSFV strain Brescia
virulence determinant was identical in strain CS, consistent with
strong reactivity of these viruses with mAb WH303 and
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nant associated with attenuation of Brescia/CS E2 chimeras
(Risatti et al., 2005a). Indeed, such a determinant is currently
being mapped in the carboxyl terminal half of E2, downstream
of mAb WH303 epitope (Risatti et al., unpublished data).
Notable is the association of the novel CSFV virulence
determinant found here with the mAb WH303 epitope. Recent
studies support the target epitope of mAb WH303 as an
immunodominant feature of CSFV. Neutralizing monoclonal
antibodies which bind the SPTxL motif within the WH303
epitope (SPTTL) were independently generated using a phage-
displayed random peptide library of CSFV E2 and Erns (Zhang
et al., 2006). The mAbWH303 is also highly specific for CSFV,
strongly reactive with all known strains and failing to react with
E2 encoded by other pestiviruses (Edwards et al., 1991).
Consistent with this reactivity, amino acid sequences mapped to
the mAbWH303 epitope are invariant among sequenced strains
of CSFVand divergent from homologous sequences encoded by
BVDV and BDV (data not shown). Such conservation in
epitope sequence and reactivity bolsters rationale for WH303
use in diagnostics, but conversely suggests that engineering the
epitope to serve as a negative marker could aid in rational
design of a CSF vaccine. Epitope conservation also suggests
that the CSFV-specific sequences in the WH303 epitope of E2,
identified here as a CSFV virulence determinant, involve a
mechanism specific and critical for CSFV infection.
Although the mechanism by which the WH303 epitope
affects virulence of CSFV is unknown, attenuating mutations in
the E2 glycoprotein conceivably involve aspects of virus
attachment and/or efficient entry into critical target cells in vivo.
Anchored to the virion envelope, pestivirus E2 appears as both
homo and heterodimers linked by disulfide bridges (Thiel et al.,
1991; Wang et al., 2004; Weiland et al., 1990) and, along with
Erns (Hulst and Moormann, 1997) and E1 (Wang et al., 2004),
has been shown to be important for virus-receptor binding and
host-cell specificity. The bovine pathogen BVDVengineered to
express the complete E2 gene of BDV, a sheep pestivirus,
retained its ability to form plaques in sheep cell cultures but lost
its ability to form plaques in bovine kidney (MDBK) cells, a
phenotype associated with 100-fold decrease in virus yield and
not complete loss of replication by the BVDV/BDV E2 chimera
in MDBK (Liang et al., 2003). Similarly, BVDV strain CP7
engineered to express the complete E2 gene of CSFV strain
Alfort 187 acquired the ability to propagate efficiently in
porcine cells but not in bovine cells (Reimann et al., 2004). On
the other hand, CSFV strain C engineered to express
homologous BVDV sequences in the amino terminus of E2
demonstrated a 10-fold decrease in virus progeny yield in swine
kidney (SK6) cells. While this impaired growth in SK6 cells
resembled wild-type BVDV, the amino-terminal region of
BVDV E2 failed to impart on the CSFV/BVDV E2 chimera the
BVDV-like ability to infect fetal bovine epithelial cells (van
Gennip et al., 2000). This observation is consistent with results
presented here: CSFV engineered to express BVDV-like
sequences at the WH303 epitope in T4v and T5v mutants
demonstrated a 10-fold reduction in viral progeny yield in SK6
cells relative to BICv, T1v, T2v and T3v (Fig. 2A) but lackedthe ability to replicate efficiently in bovine kidney cells
(MDBK) (data not shown). Thus, while BVDV-like residues
contained in T4v and T5v are sufficient to affect replication of
CSFV in SK6 cells and attenuate the virus in vivo, they are
insufficient in imparting a wild-type BVDV host-range
phenotype in vitro.
Also suggestive of a role for E2 mutations in virus
attachment and/or entry was the small plaque phenotype
exhibited by T4v and T5v, in which mAb WH303 epitope
mutations imparted a plaque size reduction relative to parental
BICv in SK6 cells (Fig. 2B). Although an association between
in vitro plaque size reduction and in vivo attenuation of CSFV
has yet to be firmly established, certain observations suggest a
relationship. While serially passed, heparan sulfate binding-
dependent variants of CSFV strain Brescia found to produce
reduced plaque size and contain a single amino acid mutation in
the Erns protein remained virulent in pigs (Hulst et al., 2000,
2001), other Brescia-derived viruses producing reduced plaque
size and containing recombinant mutations in E1 (Risatti et al.,
2005b) and E2 (Risatti et al., 2005a) were attenuated in swine.
Finally, BVDV strain NADL demonstrated a small plaque
phenotype in SK6 cells similar to that of T4v and T5v (data not
shown), again suggesting that BVDV-like mutations in the
WH303 epitope impart to CSFV similar capabilities for
attachment and/or spreading in vitro and inability to produce
disease in vivo.
In summary, a novel CSFV genetic virulence determinant
associated with the WH303 mAb epitope within the E2
glycoprotein has been identified. Interestingly, progressively
added mutations within the epitope correlated with incremental
loss of mAb WH303 reactivity and virulence in vivo, indicating
that normally invariant sequence within the mAb WH303
epitope is critical for CSFV virulence in swine. Although the
mechanism of attenuation remains unknown, the complete
attenuation of CSFV mutants containing BVDV-like sequence
within the epitope also suggested a link between the lack of the
CSFV epitope sequence and the inability of other pestiviruses
(BVDV and BDV) to induce disease in swine. Improving the
understanding of the genetic basis of CSFV virulence will
permit rational design of live attenuated CSF vaccines of
enhanced safety, efficacy and utility. Specifically, engineering
of the WH303 epitope as both a means of viral attenuation and
means to removeWH303 reactivity may ultimately prove useful
in rational design of attenuated marker CSF vaccines.
Materials and methods
Viruses and cells
Swine kidney cells (SK6) (Terpstra et al., 1990), free of
BVDV, were cultured in Dulbecco's minimal essential medium
(DMEM) (Gibco, Grand Island, NY) with 10% fetal calf serum
(FCS) (Atlas Biologicals, Fort Collins, CO). CSFV Brescia
strain was propagated in SK6 cells and used for the construction
of an infectious cDNA clone (Risatti et al., 2005a). Titration of
CSFV from clinical samples was performed using SK6 cells in
96 well plates (Costar, Cambridge, MA). Viral infectivity was
100 G.R. Risatti et al. / Virology 355 (2006) 94–101detected, after 4 days in culture, by immunoperoxidase assay
using the CSFV monoclonal antibodies WH303 or WH308
(Edwards et al., 1991) and the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA) (Risatti et al., 2003). Titers were
calculated using the method of Reed and Muench (1938) and
expressed as TCID50/ml. As performed, test sensitivity was
≥ log10 1.8 TCID50/ml.
Construction of CSFV infectious clones (ICs) T1–5
A full-length IC of the virulent Brescia isolate (pBIC) (Risatti
et al., 2005a) was used as a template in which six residues of the
WH303 epitope (TAVSPTTLR) between residues 829 to 837 of
E2 were mutated to reflect those of homologous residues present
in the BVDV isolate NADL (TSFNMDTLA) (Lin et al., 2000).
Mutations were added progressively, yielding five IC for rescue
of the following viral mutants: T1v (TSFSPTTLR), T2v
(TSFNPTTLR), T3v (TSFNMTTLR), T4v (TSFNMDTLR)
and T5v (TSFNMDTLA) (Fig. 1). Mutations were introduced
by site-directed mutagenesis using the QuickChange XL Site-
Directed Mutagenesis kit (Stratagene, Cedar Creek, TX)
performed per manufacturer's instructions and using primers
described in Table 4.
In vitro rescue of CSFV brescia and T1v–T5v mutant viruses
Full-length genomic clones were linearized with SrfI and in
vitro transcribed using the T7 Megascript system (Ambion,
Austin, TX). RNA was precipitated with LiCl and transfected
into SK6 cells by electroporation at 500 V, 720 ohms and 100W
with a BTX 630 electroporator (BTX, San Diego, CA). Cells
were plated in 12 well plates and 25 cm2 flasks and incubated
for 4 days at 37 °C and 5% CO2. Virus was detected by
immunoperoxidase staining described above, and stocks of
rescued viruses were stored at −70 °C.
DNA sequencing and analysis
Full-length clones and in vitro rescued viruses were
completely sequenced with CSFV specific primers by the
dideoxynucleotide chain-termination method (Sanger et al.,
1977). Viruses recovered from infected animals were sequenced
in the mutated area. Sequencing reactions were prepared with
the Dye Terminator Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA). Reaction products were sequenced on a
PRISM 3730×l automated DNA Sequencer (Applied Biosys-
tems). Sequence data were assembled with the Phrap softwareTable 4







a Only forward primer sequences are provided. Reverse primers correspond to theprogram (http://www.phrap.org), with confirmatory assemblies
performed using CAP3 (Huang and Madan, 1999). The final
DNA consensus sequence represented an average five-fold
redundancy at each base position. Sequence comparisons were
conducted using BioEdit software (http://www.mbio.ncsu.edu/
BioEdit/bioedit.html).
Animal infections
Each of the T1v–T5v mutants was initially screened for its
virulence phenotype in swine relative to virulent Brescia virus.
Swine used in all animal studies here were 10 to 12 weeks
old, 40-pound commercial breed pigs inoculated intranasally
with 105 TCID50 of either mutant or wild-type virus. For
screening, 12 pigs were randomly allocated into 6 groups of 2
animals each, and pigs in each group were inoculated with
one of the T1v–T5v mutants or BICv. Pigs kept in isolation
rooms were observed throughout the experiment and clinical
scores were recorded based on a scoring system described by
Mittelholzer et al. (2000) with modifications. Briefly,
observed clinical parameters include liveliness, body tension,
body shape, gait, skin condition, eyes condition, appetite,
defecation and food leftovers. Scores varied from normal=0
to severe CSF symptoms=3. Scores for all clinical para-
meters were added and plotted. Body temperature variations
were assessed daily, with values above 104 °F considered as
fever.
To assess the effect of T5v mutations on virus shedding and
distribution in different organs during infection, 10 pigs were
randomly allocated into 2 groups of 5 animals each and
inoculated with T5v or BICv. One pig per group was sacrificed
at 2, 4, 6, 8 and 14 DPI. Blood, nasal swabs and tonsil scraping
samples were obtained from pigs at necropsy. Tissue samples
(tonsil, mandibular lymph node, spleen and kidney) were snap-
frozen in liquid nitrogen for virus titration.
For protection studies, 12 pigs were randomly allocated into 3
groups of 4 animals each. Pigs in groups 1 and 2 were inoculated
with T5v, animals in group 3 were mock-infected. At 3 DPI
(group 1) or 21 DPI (group 2), animals were challenged with
BICv along with animals in group 3. Clinical signs and body
temperature were recorded daily throughout the experiment as
described above. Blood, serum, nasal swabs and tonsil scrapings
were collected at times after challenge, with blood obtained from
the anterior vena cava in EDTA-containing tubes (Vacutainer)
for total and differential white blood cell counts. Total and
differential white blood cell and platelet counts were obtained
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